Alzamend Neuro is trading at $1.30, up 16.07% in pre-market, with the catalyst unclear. - No company-specific announcement explaining the October 23 move was found; the latest listed release was September 16, announcing it regained Nasdaq listing compliance. - Available market context is mixed and does not establish a broader-market explanation for the rise. - No volume or trading-activity data was provided.